
    
      Randomized, double-blind, placebo-controlled clinical trial of pitavastatin for 2 years
      comparing the effect of study drug versus placebo on vascular measures in at least 354
      adolescents with excess adiposity and CDO (defined as high non-HDL-C + high TG/HDL-C ratio or
      low HDL-C). Enrollment will take place over 36 months.
    
  